ClinicalTrials.gg
Drug

Deuruxolitinib clinical trials

Also written CTP-543.

studies test it
23
open now
2
in phase 3
6
first study started
2016

How each study uses Deuruxolitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Deuruxolitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Jul 2024 · LEQSELVI · NDA 217900 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Deuruxolitinib
2

Development codes

CTP-543
19

Studies by the year they started

23 studies that test it; most in 2022 (6)

Studies that test Deuruxolitinib, by start year
YearStudies
20162
20171
20195
20202
20215
20226
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
5
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 0

Concert Pharmaceuticals (19) · Sun Pharmaceutical Industries, Inc. (3) · Sun Pharma Japan Limited (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test Deuruxolitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses Deuruxolitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test Deuruxolitinib →

Codes

What other systems call Deuruxolitinib · ClinicalTrials.gg INT002133

  • MeSH (NLM) C000731752DeuruxolitinibOne source NLM
  • UNII (FDA) 0CA0VSF91YDEURUXOLITINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q123485858deuruxolitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C175770DeuruxolitinibOne source FDA
  • DrugBank DB18847One source Wikidata

Also registered as deuruxolitinib phosphate (UNII 8VJ43S4LCM).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.